Medline Inc.
NASDAQ:MDLN · NASDAQ Global Select
-$0.42 today
Vol 13.95M · Avg 9.27M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 4 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Net Income | $1.2B -3.4% | $1.2B +412.8% | $234.0M +1036.0% | -$25.0M | $498.8M | $487.6M | $476.4M |
| Depreciation & Amortization | $1.0B +3.5% | $977.0M +2.7% | $951.0M +1.9% | $933.0M | $1.2B | $374.2M | $1.2B |
| Deferred Income Tax | $0 +100.0% | -$24.0M +0.0% | -$24.0M -71.4% | -$14.0M | $1.2B | $1.4B | -$1.5B |
| Stock-Based Compensation | $0 | $0 | $0 | $0 | $623.4M | $489.0M | $354.6M |
| Change in Working Capital | -$783.0M -16.0% | -$675.0M -439.2% | $199.0M +121.7% | -$919.0M | $484.8M | $350.4M | -$1.6B |
| Accounts Receivables | -$355.0M -38.7% | -$256.0M -67.3% | -$153.0M +59.3% | -$376.0M | $1.3B | $592.6M | $1.3B |
| Inventory | -$264.0M +51.6% | -$545.0M -222.7% | $444.0M +327.7% | -$195.0M | $854.4M | $1.0B | $1.2B |
| Accounts Payables | $73.0M -31.1% | $106.0M -22.1% | $136.0M +232.0% | -$103.0M | $657.0M | $948.2M | -$1.5B |
| Other Working Capital | -$237.0M -1285.0% | $20.0M +108.8% | -$228.0M +6.9% | -$245.0M | $1.3B | $567.4M | $1.3B |
| Other Non-Cash Items | $357.0M +22.7% | $291.0M -10.5% | $325.0M +53.3% | $212.0M | $1.2B | $1.4B | -$1.5B |
| Operating Cash Flow | $1.7B -1.4% | $1.8B +5.0% | $1.7B +801.1% | $187.0M | $5.5B | $7.2B | $8.9B |
| Capital Expenditures | -$447.0M -22.8% | -$364.0M -27.7% | -$285.0M -12.2% | -$254.0M | $1.0B | $664.0M | $1.4B |
| Acquisitions (Net) | $6.0M +100.5% | -$1.1B -6937.5% | -$16.0M +5.9% | -$17.0M | $769.0M | $937.0M | $1.1B |
| Purchases of Investments | $0 | $0 +100.0% | -$16.0M | $0 | $578.6M | $444.2M | $1.4B |
| Sales of Investments | $0 | $0 -100.0% | $5.0M -28.6% | $7.0M | $1.0B | $822.2M | $318.2M |
| Other Investing Activities | -$33.0M -1000.0% | -$3.0M | $0 | $0 | $862.8M | $616.4M | $370.0M |
| Investing Cash Flow | -$474.0M +68.3% | -$1.5B -378.5% | -$312.0M -18.2% | -$264.0M | $3.1B | $4.8B | $6.4B |
| Debt Repayment | -$4.1B -5356.0% | -$75.0M +2.6% | -$77.0M -26.2% | -$61.0M | $602.4M | $680.8M | $759.2M |
| Common Stock Issued | $7.0B | $0 | $0 | $0 | $610.8M | $778.8M | $946.8M |
| Common Stock Repurchased | -$2.0B -9915.0% | -$20.0M | $0 | $0 | $486.2M | $351.8M | -$1.6B |
| Dividends Paid | -$518.0M | $0 +100.0% | -$114.0M | $0 | -$1.6B | $535.2M | $613.6M |
| Other Financing Activities | -$36.0M +97.6% | -$1.5B | $0 +100.0% | -$23.0M | $720.0M | -$1.6B | $1.3B |
| Financing Cash Flow | $399.0M +124.7% | -$1.6B -744.5% | -$191.0M -127.4% | -$84.0M | $10.5B | $12.2B | $13.9B |
| Effect of Forex Changes | $20.0M +900.0% | $2.0M -99.5% | $403.0M +150.3% | $161.0M | $1.4B | $1.3B | $1.1B |
| Net Change in Cash | $1.7B +226.5% | -$1.3B -184.2% | $1.6B | $0 | -$15.5B | $3.2B | $4.9B |
| Free Cash Flow | $1.3B -7.7% | $1.4B +0.4% | $1.4B +2189.6% | -$67.0M | $14.3B | $8.6B | -$16.8B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
ResMed Inc.
NYSE:RMD
$27.26B
The Cooper Companies, Inc.
NASDAQ:COO
$12.85B
Avantor, Inc.
NYSE:AVTR
$6.54B
Bausch + Lomb Corporation
NYSE:BLCO
$5.32B
Netskope, Inc. Class A Common Stock
NASDAQ:NTSK
$3.61B
LeMaitre Vascular, Inc.
NASDAQ:LMAT
$2.13B
Kestra Medical Technologies, Ltd.
NASDAQ:KMTS
$1.17B
Lumexa Imaging Holdings, Inc. Common Stock
LMRI
$887.79M
InfuSystem Holdings, Inc.
AMEX:INFU
$186.28M
Black Rock Coffee Bar, Inc. Class A Common Stock
NASDAQ:BRCB
$136.95M
SEC Filings
Recent regulatory filings
No filings found.
Does MDLN generate free cash flow?
Medline Inc. (MDLN) generated $1.30B of free cash flow in fiscal 2025.
How much operating cash flow does MDLN produce?
Operating cash flow was $1.74B, before capital expenditures of $447.00M.
Explore More
Continue the stock analysis
Jump to another research area for this company.